Nurix (NRIX) soars 18.7% on encouraging blood cancer treatment trial
I'm PortAI, I can summarize articles.
Nurix Therapeutics Inc. (NASDAQ:NRIX) saw its stock rise by 18.7% to $21.47, marking a fourth consecutive day of gains. The surge was driven by promising results from a blood cancer treatment trial, making it one of the top performers amid a market downturn.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments